TGFβ and Smad Signaling Components in Esophageal Adenocarcinoma

食管腺癌中的 TGFβ 和 Smad 信号传导成分

• 批准号: 10417021
• 负责人: Andrew Edward Blum
• 金额: --
• 依托单位: LOUIS STOKES CLEVELAND VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10417021
• 关键词: 3-Dimensional; Adenocarcinoma Cell; Age; Award; Barrett Esophagus; Binding; Biomedical Research; Biopsy; Cancer Biology; Caucasians; Cell Line; Cells; ChIP-seq; Chemicals; Chemoresistance; Clinical; Co-Immunoprecipitations; Competence; Computer Analysis; Data; Dependence; Detection; Development; Diagnosis; Disease; Disease model; Distal; Doxycycline; Dysplasia; Early Diagnosis; Early Promoters; Early treatment; Elements; Endoscopy; Environment; Epithelial Cells; Esophageal Adenocarcinoma; Esophagus; Ethnic Origin; Family; Fluorouracil; Gastroenterologist; Gastroenterology; Gender; General Population; Genes; Genomics; Goals; Growth; Hyperactivity; Immune; Immunoprecipitation; Incidence; Induction of Apoptosis; Inhibition of Cell Proliferation; Intestines; Lesion; Ligands; Malignant Neoplasms; Malignant neoplasm of esophagus; Malignant neoplasm of gastrointestinal tract; Maps; Mediating; Mediator of activation protein; Mentors; Modeling; Molecular; Molecular Carcinogenesis; Mucous Membrane; Mus; Mutation; Neoplasm Metastasis; Neoplasms; Non-Malignant; Obesity; Oncogenic; Oral; Organoids; Pathway interactions; Patients; Physicians; Population; Pre-Clinical Model; Prevalence; Property; Research; Research Proposals; Resistance; Risk; Risk Factors; Role; Scientist; Signal Pathway; Signal Transduction; Survival Rate; Systems Biology; Testing; Tobacco use; Training; Transforming Growth Factor beta; Transforming Growth Factor beta Receptors; Translational Research; Tumor Suppressor Proteins; Unresectable; Veterans; Xenograft Model; Xenograft procedure; addiction; arm; biomarker development; career; career development; chemotherapy; clinical application; design; established cell line; experience; genetic analysis; genome-wide; high risk; human model; improved; improved outcome; in vivo; inhibitor; innovation; knock-down; male; mutant; new therapeutic target; novel; novel therapeutic intervention; patient derived xenograft model; phase II trial; premalignant; prevent; prognostication; programs; protein protein interaction; receptor; screening; skills; small hairpin RNA; small molecule inhibitor; standard care; success; synergism; tandem mass spectrometry; targeted treatment; transcriptome; transcriptome sequencing; tumor; tumor growth; tumor progression; tumor xenograft; tumorigenic

Esophageal adenocarcinoma (EAC) is a highly fatal cancer with 5-year survival under 20%. Alarmingly, the incidence of cancer of the esophagus has increased significantly over the past 30 years. EAC arises from a known precursor lesion, termed Barrett's esophagus (BE), that can be easily recognized at endoscopy. However, current clinical strategies of screening and surveillance are inadequate and EAC diagnosis often occurs at advanced and unresectable stages of the disease. Veterans are increased risk for BE and EAC compared to the general population due to increased risk factors (including age >50 and male gender). There is an urgent clinical need to improve strategies for the detection, prognostication, and treatment of BE and EAC. This translational research proposal aims to elucidate the molecular carcinogenesis of EAC, with the ultimate goal of reducing the burden associated with this deadly cancer. We used integrative computational and genetic analyses to identify common mechanisms that underlie EAC tumor progression. We identified that the TGFβ pathway is highly active in EAC compared to non-malignant BE. The TGFβ/Smad pathway has tumor suppressive properties in epithelial cells, including inhibition of cell proliferation and induction of apoptosis, and the functional TGFβ pathway elements are frequently lost through mutation in gastrointestinal malignancies. However, in established cancers TGFβ signaling can promote invasion and metastasis, suggesting opposing roles for TGFβ signaling that depend on disease stage. In contrast, our preliminary findings show that the TGFβ pathway fails to inhibit the growth of pre-malignant dysplastic BE cells in addition to EAC cells; on the contrary TGFβ induces growth of EAC cells even in the presence of functional TGFβ pathway components. Further, the pro-tumorigenic TGFβ pathway effects are evident in EAC that are either wild-type or mutant for Smad4, a canonical mediator of TGFβ signaling. Together, our preliminary studies indemnify an alternative model for the oncogenic TGFβ with early hyperactivation of an unconventional, Smad4 independent, Smad2/3 dependent pathway. Our findings have important translational implications. In Aim 1, we will investigate the molecular determinants of the oncogenic TGFβ signaling in EAC carcinogensis. In Aim 2, we will assess impact of disrupting oncogenic TGFβ signaling in highly relevant pre-clinical models of EAC. Of particular importance, LY2157299 (galunisertib), an orally bioavailable small molecule inhibitor of the TGFβ Receptor – Type 1, is currently being tested in Phase II trials in other malignancies and represents a new therapeutic strategy that can be rapidly evaluated for this lethal cancer. This study is highly innovative and will improve our ability to both prevent and treat cancer of the esophagus. The scientific proposal and career development activities described here will serve an essential role in my development as a clinical gastroenterologist at the VA and as a scientist with research program aimed at improving early detection and treatment of gastrointestinal cancer. Through this CDA-2 award, I will receive additional training and experience related to cancer biology, systems biology, and pre-clinical models of human cancer that will be essential to reach my goal. Also, in this rich mentored environment, I will develop skills required to perform independent research.

食管腺癌（EAC）是一种高致死率的癌症，5年生存率低于20%。令人担忧的是,